Corrado Lodigiani
Corrado Lodigiani is an expert in Hematology at IRCCS Humanitas Research Hospital (Italy). As of July 2026, ScienceLeadR ranks Corrado Lodigiani in the top 1% of experts worldwide for Embolism and Thrombosis. Corrado Lodigiani has authored 144 publications, the most recent in 2026, and is an investigator in 25 clinical trials, 1 of them ongoing. SLR score: 541 (community average: 125). How the SLR is computed.
LeadR Profile
Hematology
Subspecialties: Cardiology - Neurology - Public Health
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2009 - 2026
Number : 144
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Thrombocytopenia in carriers and patients with antiphospholipid syndrome: insights from the nationwide START-APS registry. PMID 42303888 — registries, antibodies, antiphospholipid, antibodies, internal medicine, antiphospholipid syndrome, prevalence, thrombocytopenia | Intern Emerg Med | 2026 | 0 |
| Patient-reported outcomes after upper-extremity deep vein thrombosis due to compression syndromes: a multinational longitudinal retrospective study. PMID 41704797 — quality of life, upper extremity deep vein thrombosis, retrospective studies, outcome assessment, health care, patient reported outcome measures, postthrombotic syndrome, therapeutics, venous thromboembolism, thrombosis, veins | Res Pract Thromb Haemost | 2026 | 0 |
| Burden of Atherosclerosis and Outcomes of Acute Pulmonary Embolism: A Post Hoc Analysis of the Hokusai-VTE Trial. PMID 41195787 — heart diseases, embolism, hemorrhage, vascular diseases, pulmonary embolism, atherosclerosis, venous thromboembolism, prognosis | J Am Heart Assoc | 2025 | 0 |
| Management of recurrent venous thromboembolism during anticoagulant treatment in patients with cancer: a prospective cohort study. PMID 40915572 — anticoagulants, thromboembolism, hemorrhage, neoplasms, cohort studies, therapeutics, venous thromboembolism, thrombosis, heparin, low-molecular-weight, direct-acting oral anticoagulants | J Thromb Haemost | 2025 | 0 |
| COVID-19: A Disease Driven by Protease/Antiprotease Imbalance? A Specific Review Five Years into the Pandemic. PMID 40799952 — fibrinolysis, cytokine release syndrome, biomarkers, thrombophilia, covid-19, peptide hydrolases, pandemics, protease inhibitors, serpins | Infect Drug Resist | 2025 | 0 |
Clinical Studies 25
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 3
Ongoing Clinical Trials
Ongoing trial started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Hip Fracture Surgery Arterial and Venous Thrombotic Events Prevention NCT07228663 — pilots, anticoagulants, enoxaparin, thromboembolism, rivaroxaban, heparin, aspirin, tinzaparin, dalteparin, venous thromboembolism, heparin, low-molecular-weight, fondaparinux, direct-acting oral anticoagulants, apixaban | Phase 3 | Not yet recruiting | 2025 |
LeadR Networks
Main global connection map